BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

538 related articles for article (PubMed ID: 16447119)

  • 1. CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients.
    Goujard C; Bonarek M; Meyer L; Bonnet F; Chaix ML; Deveau C; Sinet M; Galimand J; Delfraissy JF; Venet A; Rouzioux C; Morlat P;
    Clin Infect Dis; 2006 Mar; 42(5):709-15. PubMed ID: 16447119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
    Hoen B; Cooper DA; Lampe FC; Perrin L; Clumeck N; Phillips AN; Goh LE; Lindback S; Sereni D; Gazzard B; Montaner J; Stellbrink HJ; Lazzarin A; Ponscarme D; Staszewski S; Mathiesen L; Smith D; Finlayson R; Weber R; Wegmann L; Janossy G; Kinloch-de Loes S;
    Clin Infect Dis; 2007 Aug; 45(3):381-90. PubMed ID: 17599319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early levels of HIV-1 DNA in peripheral blood mononuclear cells are predictive of disease progression independently of HIV-1 RNA levels and CD4+ T cell counts.
    Rouzioux C; Hubert JB; Burgard M; Deveau C; Goujard C; Bary M; Séréni D; Viard JP; Delfraissy JF; Meyer L;
    J Infect Dis; 2005 Jul; 192(1):46-55. PubMed ID: 15942893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170.
    Skiest DJ; Su Z; Havlir DV; Robertson KR; Coombs RW; Cain P; Peterson T; Krambrink A; Jahed N; McMahon D; Margolis DM;
    J Infect Dis; 2007 May; 195(10):1426-36. PubMed ID: 17436222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Despite being highly diverse, immunovirological status strongly correlates with clinical symptoms during primary HIV-1 infection: a cross-sectional study based on 674 patients enrolled in the ANRS CO 06 PRIMO cohort.
    Ghosn J; Deveau C; Chaix ML; Goujard C; Galimand J; Zitoun Y; Allègre T; Delfraissy JF; Meyer L; Rouzioux C;
    J Antimicrob Chemother; 2010 Apr; 65(4):741-8. PubMed ID: 20167586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A high HIV DNA level in PBMCs at antiretroviral treatment interruption predicts a shorter time to treatment resumption, independently of the CD4 nadir.
    Piketty C; Weiss L; Assoumou L; Burgard M; Mélard A; Ragnaud JM; Bentata M; Girard PM; Rouzioux C; Costagliola D;
    J Med Virol; 2010 Nov; 82(11):1819-28. PubMed ID: 20872707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.
    Lapadula G; Torti C; Maggiolo F; Casari S; Suter F; Minoli L; Pezzoli C; Di Pietro M; Migliorino G; Ouiros-Roldan E; Ladisa N; Sighinolfi L; Costarelli S; Carosi G;
    Antivir Ther; 2007; 12(6):941-7. PubMed ID: 17926648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended antiretroviral treatment interruption in HIV-infected patients with long-term suppression of plasma HIV RNA.
    Achenbach CJ; Till M; Palella FJ; Knoll MD; Terp SM; Kalnins AU; Murphy RL
    HIV Med; 2005 Jan; 6(1):7-12. PubMed ID: 15670246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
    AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
    Moore RD; Keruly JC
    Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS.
    O'Brien WA; Hartigan PM; Martin D; Esinhart J; Hill A; Benoit S; Rubin M; Simberkoff MS; Hamilton JD
    N Engl J Med; 1996 Feb; 334(7):426-31. PubMed ID: 8552144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticardiolipin antibodies in HIV infection are independently associated with antibodies to the membrane proximal external region of gp41 and with cell-associated HIV DNA and immune activation.
    Martinez V; Diemert MC; Braibant M; Potard V; Charuel JL; Barin F; Costagliola D; Caumes E; Clauvel JP; Autran B; Musset L;
    Clin Infect Dis; 2009 Jan; 48(1):123-32. PubMed ID: 19035778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increase of HIV-1 pro-viral DNA per million peripheral blood mononuclear cells in patients with advanced HIV disease (CD4<200 cells/mm3) receiving interleukin 2 combined with HAART versus HAART alone (ANRS-082 trial).
    Delaugerre C; Gourlain K; Tubiana R; Carcelain G; Marcelin AG; Chouquet C; Mouroux M; Duvivier C; Autran B; Costagliola D; Katlama C; Calvez V
    Antivir Ther; 2003 Jun; 8(3):233-7. PubMed ID: 12924540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heat-denatured human immunodeficiency virus type 1 protein 24 antigen: prognostic value in adults with early-stage disease.
    Sterling TR; Hoover DR; Astemborski J; Vlahov D; Bartlett JG; Schupbach J
    J Infect Dis; 2002 Oct; 186(8):1181-5. PubMed ID: 12355373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA.
    Goicoechea M; Smith DM; Liu L; May S; Tenorio AR; Ignacio CC; Landay A; Haubrich R
    J Infect Dis; 2006 Jul; 194(1):29-37. PubMed ID: 16741879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy.
    Khanna N; Opravil M; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Weber R; Hirschel B; Battegay M; Kaufmann GR;
    Clin Infect Dis; 2008 Oct; 47(8):1093-101. PubMed ID: 18783328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Natural history of human immunodeficiency virus infection in a cohort of Chilean patients].
    Vial PA; Ferreccio C; Abarca K; Ortiz E; Noriega M; Pérez C; Labarca J; Torres M; Ferrés M; González C; Acuña G
    Rev Med Chil; 1996 May; 124(5):525-35. PubMed ID: 9035503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of maintaining highly active antiretroviral therapy on AIDS events among patients with late-stage HIV infection and inadequate response to therapy.
    Gandhi T; Wei W; Amin K; Kazanjian P
    Clin Infect Dis; 2006 Mar; 42(6):878-84. PubMed ID: 16477568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD4 cell-monitored treatment interruption in patients with a CD4 cell count > 500 x 106 cells/l.
    Mussini C; Bedini A; Borghi V; Guaraldi G; Esposito R; Barchi E; Enilia R; Cozzi-Lepri A; Philips AN; Ortolani P; Bratt G; Eriksson LE; Sighinolfi L; Cossarizza A; d'Arminio Monforte A; De Luca A; Di Giambenedetto S; Antinori A;
    AIDS; 2005 Feb; 19(3):287-94. PubMed ID: 15718839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Value of HIV-1 viral load and CD4 lymphocyte count as determinants of progression to AIDS and survival].
    Romeu J; Balagué M; Ruiz L; Marfil S; Puig T; Arnó A; Veny A; Tural C; Sirera G; Clotet B
    Med Clin (Barc); 1998 Jun; 110(20):761-7. PubMed ID: 9666416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.